key: cord-0898449-vas9ep03 authors: Girardeau, Y.; GALLOIS, Y.; DE BONNECAZE, G.; ESCUDE, B.; LAFONT, C.; CHATELLIER, G.; MARX, M. title: Confirmed central olfactory system lesions on brain MRI in COVID-19 patients with anosmia: a case-series date: 2020-07-17 journal: nan DOI: 10.1101/2020.07.08.20148692 sha: 58443ec3424680cb19f5c8758a914d7448ef536b doc_id: 898449 cord_uid: vas9ep03 Objective: Anosmia has been listed as a key-symptom associated with the COVID-19 infection. Because it often occurs without any sign of rhinitis, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia caused by SARS-CoV2 could be the result of brain damage. Methods: We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia. Each patient prospectively underwent a validated olfactory test (Sniffin Sticks test) and a brain MRI. Results: Hypersignal intensity lesions of the central olfactory system were found in 3 subjects on 3D T2 FLAIR and 2D T2 High Resolution images with a lesion involving the olfactory bulbs and/or the orbitofrontal cortex. These 3 subjects showed a severe and persistent loss of smell on the olfactory test. Mucosal hyperplasia of the upper nasal cavities was found in two other subjects with significant smell disorders. There was no MRI anomaly in two subjects with good smell restoration. Conclusions: Anomalies of the central olfactory system could be responsible for anosmia in patients with COVID-19 infection. Further studies are needed to assess the impact on long-term functional prognosis of these lesions. i v e Anosmia has been listed as a key-symptom associated with the COVID-19 infection. Because it often occurs without any sign of rhinitis, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia caused by SARS-CoV2 could be the result of brain damage. We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia. Each patient prospectively underwent a validated olfactory test (Sniffin' Sticks test) and a brain MRI. Introduction COVID-19 is currently responsible for an unprecedented global pandemic (1) . However, the actual number of cases is most certainly underestimated due to the scarcity of diagnostic tests and the large share of pauci-symptomatic forms (2) . In addition to respiratory symptoms (3), anosmia appears to be frequently associated with the COVID-19 (4) (5) (6) . Accordingly, on March 22, 2020, the American Academy of Otolaryngology proposed adding anosmia to the list of symptoms associated to COVID-19 (7). Post infectious anosmia is well known by otolaryngologists (8) (9) (10) . It is the main cause with rhinosinus lesions, and traumatic causes (11) . However, the exact pathophysiological mechanisms of postinfectious anosmia remain poorly understood (12) . It could involve damage to the olfactory epithelium, to the nerves or the olfactory bulb, or even to the central nervous system (12) . The latter hypothesis could be one of the mechanisms for anosmia cases reported in the COVID-19 epidemic. Two recent publications support it (13, 14) , both relating to a very similar coronavirus, the SARS-CoV-1. Our hypothesis was that anosmia caused by SARS-CoV2 could be the result of brain damage. A case series study was conducted on 10 consecutive COVID-19 patient with anosmia who prospectively underwent a brain MRI to identify brain lesions. The day before the brain MRI, patients were asked to self-assess the loss of smell (SAS) between: 0 "normal smell perception" and 100 "total loss of sense of smell" and excluded patient who reported a full recovery of their olfaction, and tested included patient for olfactory function using an international validated psychophysical procedure, the Sniffin' Sticks test (15) , where patients have to identify the correct smell between four propositions for 12 different smells. According to the results, the age and the sex, patients were classified as anosmic, hyposmic or normosmic. The 10 participants were examined on the same 1.5 Four were current smokers. One had an every day alcohol consumption. Five took medications during the two weeks before the onset of anosmia. Six had an history of allergies and 5 to inhaled allergens (pollens and mites). None of them had an history of rhinosinusal disorder or head trauma. Only 1 had an history of asthma. Anosmia was the first symptom for five. Only 1 had cough and 3 had fever. Fatigue and headache were the most common symptoms recorded in 9 and 7 patients, respectively. All had experienced a total olfactory loss. Four experienced phantosmia and 3 parosmia. The loss of the function was sudden for 8 patients. Seven had also an impairment of their sense of taste. The median time interval between the onset of anosmia and the brain MRI was 28 days (range of 15-32 days). According to the Sniffin' Sticks test, 3 patients were considered as normosmic, 5 as hyposmic and 2 as anosmic the day before the brain MRI. was also significantly altered in these two patients (65/100 and 100/100). Severe headaches and retroorbital pain were also reported by the first subject. In the third subject, a hypersignal intensity lesion was found in the right orbitofrontal cortex, which includes the olfactory cortex (see figure 3) . Similarly, this participant reported a poor quality of smell (SAS: 100/100), confirmed by the Sniffin' Sticks test , 5/12 (Anosmia). Anomalies of the upper nasal cavity were found in two other cases, showing a mucosal hyperplasia of the anterosuperior ethmoidal cells. The quality of smell was also affected in these two subjects with SAS scores of 100/100 and 90/100, and corresponding olfactory performance of 11/12 and 10/12 on the Sniffin' Sticks test, classified as hyposmia. Among the five remaining subjects, three showed no anomaly on MRI, reported a good smell restoration with a score of 12/12 on the Sniffin' Stick test. In the remaining two subjects, the hypothesis of orbitofrontal cortical hypersignal intensity lesions was raised, as in the third subject aforementioned. Unfortunately, the movements during MRI acquisition time precluded any agreement between the examiners. The olfactory scores for these last two subjects were respectively 100/100 and 90/100 for SAS, and 10/12 (hyposmia) for both on the Sniffin' Stick test. Several recent studies have identified anosmia as a key-symptom in COVID-19 (4, 5) . But the mechanisms surrounding anosmia are still under debate (16) . Some authors consider that anosmia is the result of the neuro-epithelium inflammation caused by the viral infection (17) . But in the context of COVID-19, several patients experienced a total loss of smell without any signs of rhinitis (5) . Therefore, anosmia could result from damage to the central olfactory system. To the best of our knowledge, this is the first case series to report MRI anomalies of the olfactory bulbs and cortex in COVID-19 patients . Our findings suggest that COVID-19 could provoke an inflammation throughout the central olfactory system. As many other viruses (18, 19) , coronaviruses could use olfactory tract as a pathway to spread into the central nervous system. Two publications support this hypothesis, both related to a similar coronavirus, the SARS-CoV-1. The first one (13) , reports the presence of SARS-CoV-1 in brain samples of victims. The second (14) , shows that SARS-CoV-1 was able to penetrate through the olfactory nerves and spread to several brain areas in transgenic mice. Furthermore, SARS-CoV-2 is known to use ACE2 and TMPRSS2 transmembrane proteases for host cell entry and these proteins are both expressed by the olfactory epithelium cells (14, 20) . Ideally, brain MRI examinations would have been performed earlier with respect to the onset of anosmia. But the putative exposure to SARS-CoV2 for the radiologic staff for this non-urgent exploration was a real concern. Therefore, most of the brain MRI (8/10) were performed on a dedicated afternoon, more than three weeks after symptoms onset. This delay between the anosmia onset and the brain MRI resulted in the normalization of olfactory performance in 3 patients, considered as normosmic according to the Sniffin' Sticks test, although their SAS remained unfavorable ( 25/100 (N= 2) and 10/100 (N=1), 0 "normal smell perception" and 100 "total loss of sense of smell"). Eventually, only patients with confirmed hyposmia or anosmia showed lesions of the olfactory system, whether peripheral or central. In the same line, several MRI studies on patients with chronic anosmia used 3 rather than 1.5 Tesla MRI to measure the volume of the OBs and to detect subtle signs of cerebral lesions. (21) Restrictions of MRI access due to the epidemic prevented us from using such protocols which might have provided useful data. Still, our protocol was sensitive enough to demonstrate significant anomalies of the central olfactory system in 3/10 subjects, absent in the cases where the olfactory function was restored. The persistence of severe smell disorders more than 3 weeks after the symptoms onset seems related to central anomalies of the olfactory pathway. Central anomalies of the olfactory bulb and cortex could be responsible for anosmia in COVID-19 infection. These findings could have immediate consequences for the assessment and the follow-up of patients with anosmia. Further studies are needed to assess the impact on long-term functional prognosis of this identified lesions. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Clinical Characteristics of Coronavirus Disease 2019 in China Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Presentation of new onset anosmia during the COVID-19 pandemic Utility of hyposmia and hypogeusia for the diagnosis of COVID-19 AAO-HNS: Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease Postviral olfactory loss Post-infectious olfactory loss: a cohort study and update Postinfectious olfactory loss: A retrospective study on 791 patients Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center Clinical Diagnosis and Current Management Strategies for Olfactory Dysfunction: A Review The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms Sniffin" sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold Potential pathogenesis of ageusia and anosmia in COVID-19 patients Sudden and Complete Olfactory Loss Function as a Possible Symptom of COVID-19 Identification of viruses in patients with postviral olfactory dysfunction The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection MR Imaging-Based Evaluations of Olfactory Bulb Atrophy in Patients with Olfactory Dysfunction Juliette DJADI-PRAT, Pauline JOUANY, Raphäel HADJADJ, Véronique LAHMAUT, Paul AVILLACH, Anne-Sophie JANNOT. The authors declare no competing interests.